How is Ultherapy® different?
Real-time visualisation, the foundation of Ultherapy® technology, allows you to view beneath the skin’s surface, enabling a high level of precision and customisation for enhanced safety and optimal aesthetic results.2–7
Ultherapy® treats to depths of up to 4.5 mm, allowing you to target deep layers of collagen.3–6,8
Ultherapy® provides a technology that consistently heats tissue to 65°C, which is optimal for collagen denaturation.2,5,8
ULTHERAPY® AREAS OF TREATMENT

MECHANISM OF ACTION
Ultherapy® represents a remarkable evolution in aesthetic science, employing micro-focused ultrasound to create thermal coagulation points (TCPs) in dermal, subcutaneous and even the superficial muscular aponeurotic system (SMAS) tissue layers. TCPs heat tissues to the optimal temperature for collagen denaturation.3,5,8
Neocollagenesis, the body’s natural wound-healing response, commences immediately and proceeds through three phases that can produce visible results for over one year.3,8–12
PHASE 1:
INFLAMMATION

PHASE 2:
PROLIFERATION

PHASE 3:
MATURATION & REMODELLING

TREATS THE SAME DEEP TISSUE PLANES AS SURGERY12,13
Localised heating at depths of 1.5 mm, 3.0 mm, and 4.5 mm treats deeper than lasers or radiofrequency.3,5,8

Only Ultherapy® is proven to increase collagen synthesis by 42%12
Ultherapy® is A collagen creator12
In a study, patients received Ultherapy® treatment on one side of the face only, to compare results. The side treated with Ultherapy® demonstrated:12
Graph adapted from Sasaki GH, et al. ASDS Poster #103, 2018.
Standard deviations of replicate measurements are represented by error bars.
Graph adapted from Sasaki GH, et al. ASDS Poster #103, 2018.
References:
- Ulthera Press Release: Ultherapy® décolletage treatment now FDA-cleared. BioSpace website.
Available at: https://www.biospace.com/article/releases/ulthera-release-ultherapy-and-0174-d%C3%A9colletage-treatment-now-fda-cleared-/ Accessed: July 2021. - Fabi SG, et al. J Drugs Dermatol. 2019;18(5):426–432.
- ULTHERAPY EU 1001393IFU Rev N IFU, CONTROL UNIT IFU _Final.
- White WM, et al. Arch Facial Plast Surg. 2007;9(1):22–29.
- Fabi SG. Clin Cosmet Investig Dermatol. 2015;8:47–52.
- Vachiramon V, et al. J Cosmet Dermatol. 2021;20:132–137.
- Ulthera System 501(k) Summary. U.S. Food & Drug Administration website. Available at: www.accessdata.fda.gov/cdrh_docs/pdf13/k134032.pdf Accessed: July 2021.
- Dobke MK, et al. Clin Plastic Surg. 2012;39(4):399–408.
- Werschler WP & Werschler PS. J Clin Aesthet Dermatol. 2016;9(2):27–33.
- Brobst RW, et al. Facial Plast Surg Clin N Am. 2014;22:191–202.
- Sasaki GH & Tevez A. JCDSA. 2012;2:108–116.
- Stimulation of Collagen Synthesis in Human Skin Following Ultherapy. Sasaki GH, Grossman J, Misell L. Poster #103 presented at American Society for Dermatologic Surgery (ASDS) Annual Meeting, Phoenix, AZ. Oct 2018. Abstract available at: https://www.asds.net/Portals/0/PDF/annual-meeting-brochure.pdf Accessed: June 2021.
- Whitney ZB & Zito PM. Anatomy, skin, superficial musculoaponeurotic system (SMAS) fascia. In: StatPearls. Treasure Island, FL: StatPearls Publishing; 2019.
Available at: https://www.ncbi.nlm.nih.gov/books/NBK519014/ Accessed: July 2021.